Effects of an amustaline (S‐303)/glutathione pathogen reduction system on the in vitro quality of plasma and platelets in treated whole blood
Transfusion · 2026
DOI: 10.1111/trf.18484 ↗At a glance
Journal article in Transfusion, 2026. Written by M Reza Khoshi and 13 co-authors. Institution: US Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Blood Research and Review, Silver Spring, Maryland, USA. Major MEDLINE topics: Blood Platelets, Glutathione, Plasma, Blood Preservation. 19 references. Funded by: U.S. Food and Drug Administration.
Abstract (original language)
Background
A pathogen reduction (PR) system for whole blood (WB) that maintains component quality could enable a universally pathogen‐reduced blood supply. The goal of this study was to assess the effects of an amustaline (S‐303)/glutathione PR process on platelets and plasma in treated WB.
Methods
We analyzed the effects of an S‐303/glutathione PR process on platelet and plasma function in treated WB using in vitro platelet aggregation response (impedance aggregometry), expression of platelet activation markers (flow cytometry), and plasma coagulation parameters (clotting, chromogenic, and WB viscoelastic assays).
Results
At S‐303 concentrations from 0.1 to 0.4 mM, the treatment had significant, dose‐dependent effects on plasma and platelet function. Plasma clotting times were prolonged, and the largest loss of activity was in vitamin K‐dependent factors. Effects were rapid (within 15 min of treatment) and evident in clot‐based, chromogenic, and viscoelastic assays, with significant impact on clot firmness and kinetics. Platelet aggregation responses to collagen were partially preserved and S‐303 dose‐dependent, while responses to other agonists were largely eliminated. Platelets from treated WB showed an S‐303 dose‐dependent increase in surface expression of CD62P, CD63, PAC1, and phosphatidylserine, and partially retained responses to TRAP‐6 agonist.
Discussion
The results demonstrate that S‐303/glutathione PR of WB for preparation of hemostatic components is limited by detrimental off‐target effects. The pattern of detrimental effects identifies opportunities for optimization of similar approaches to PR and provides insight into the hemostatic activity of S‐303‐treated WB.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- US Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Blood Research and Review, Silver Spring, Maryland, USA.
- Cerus Corporation, Concord, California, USA.
ORCID profiles: M Reza Khoshi
Funding
- U.S. Food and Drug Administration
Cite
APA
Khoshi, M. R., Jinfessa, A., Pongerard, A., Gatmaitan, M., Sweeney, M., Lavrentieva, A., Hayashi, C., Visser, B. J., Mufti, N., Kumar, S., McGivern, D. R., Simak, J., Yegneswaran, S., & Villa, C. H. (2026). Effects of an amustaline (S‐303)/glutathione pathogen reduction system on the in vitro quality of plasma and platelets in treated whole blood. Transfusion. https://doi.org/10.1111/trf.18484
Vancouver
Khoshi MR, Jinfessa A, Pongerard A, Gatmaitan M, Sweeney M, Lavrentieva A, et al. Effects of an amustaline (S‐303)/glutathione pathogen reduction system on the in vitro quality of plasma and platelets in treated whole blood. Transfusion. 2026. doi:10.1111/trf.18484
BibTeX
@article{Khoshi2026,
author = {Khoshi, M Reza and Jinfessa, Ayantu and Pongerard, Anais and Gatmaitan, Michelle and Sweeney, Melanie and Lavrentieva, Anna and Hayashi, Cliff and Visser, Bryan J and Mufti, Nina and Kumar, Sanjai and McGivern, David R and Simak, Jan and Yegneswaran, Subramanian and Villa, Carlos H},
title = {Effects of an amustaline (S‐303)/glutathione pathogen reduction system on the in vitro quality of plasma and platelets in treated whole blood},
journal = {Transfusion},
year = {2026},
doi = {10.1111/trf.18484}
}
EUVIMED